Key result
Apixaban and rivaroxaban show differing bleeding risks in acute venous thromboembolism.
Reveals divergent bleeding outcomes between apixaban and rivaroxaban in acute venous thromboembolism, indicating distinct clinical safety profiles.
Jean-Luc Reny, Youssef Daali, Jean Terrier; Same Target but Different Bleeding Outcomes: Insights from a Randomized Apixaban-Rivaroxaban Comparison in Pati
No takes yet. Share an insight, caveat, or question.
Reny et al. (2026) studied this question. Apixaban and rivaroxaban exhibit different bleeding outcomes despite sharing the same therapeutic target in patients with acute venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: